Mutated IDH1 and IDH2 are incapable of forming α-ketoglutarate and 2-hydroxyglutarate, thereby inhibiting TET protein activity and stimulating the development of cancer (Kamdar et al., 2016). The gene discussed is IDH1; the disease is cancer.